Galderma’s relabotulinumtoxinA FDA setback shifts attention to manufacturing readiness
Discover why FDA manufacturing concerns have delayed Galderma’s relabotulinumtoxinA approval and what the company must resolve next.
Pharma & Biotech
Pharma & Biotech
How Galderma is repositioning Restylane Contour beyond cheeks into full-face structural correction
FDA approval of Restylane Contour for temple hollowing signals a shift in facial aesthetics. Discover what this means for the industry and future treatments.
Pharma & Biotech
How Galderma’s We Are All Sculptra program reframes collagen biostimulation in aesthetic medicine
Galderma launches a two-year Sculptra initiative tracking real-world outcomes. Discover what this means for regenerative aesthetics and durability claims.
Pharma & Biotech
How Galderma’s Wake Up To Restylane campaign reflects evolving aesthetics patient preferences
Explore how Galderma’s Wake Up To Restylane strategy and new IMCAS data could reshape aesthetic practice and hyaluronic acid filler adoption.